Monthly costs without coverage run approximately $300 to $400 CAD for Ozempic depending on pharmacy and dose
InThought: Standing out upon too many failures to count in this difficult-to-treat disease, povorcitinib holds its own in sustained improvements in HiSCR50 and will offer an oral alternative and, hopefully, competitive pricing to the HS market served exclusively by biologics
Expired semaglutide often appears clear, colorless, and normal to the naked eye
lighter or skipped periods suggest metabolic improvement in PCOS-pattern patients Cycle changes lasting beyond 6 months at stable weight or accompanied by severe pain, flooding, or clotting warrant gynecological evaluation, not just dose adjustment Direct answer (40-60 words) Zepbound (tirzepatide) disrupts menstrual cycles through rapid weight loss releasing stored estrogen from adipose tissue, improved insulin sensitivity changing ovulation patterns in metabolically compromised patients, and direct GLP-1 receptor activation affecting hypothalamic-pituitary-ovarian signaling
Medicare will begin covering GLP-1 medications for obesity through the Medicare GLP-1 Bridge program starting July 1, 2026, offering eligible beneficiaries access for $50 per month
doi: 10.1111/acel.12389 14 LiSWangMMaJPangXYuanJPanYet al
